English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The rate of disease progression differs among patients with degenerative cerebellar ataxia. Purpose: We determined the annual cerebellar volume atrophy rate with magnetic resonance imaging (MRI) and disease progression in ataxia with the International Cooperative Ataxia Rating Scale (ICARS) according to the subtype of cerebellar degeneration using longitudinal follow-up data. Methods: We examined 50 patients consisting of 22 cases of spinocerebellar ataxia (SCA), 17 cases of multiple system atrophy (MSA), and 11 cases of cortical cerebellar ataxia (CCA). In all patients, at least two sets of eval‐ uations including MRI and ICARS scoring were performed. A total of 146 sets of evaluations was obtained with the longest follow-up period being 77 months. The cerebellar volume of all patients (ml) was divided by each cranial AP diameter (mm) to correct for the individual head size differences as a volume index (Vdx). The an‐ nual atrophy volume in Vdx and the annual progression in the ICARS were calculated in each patients. Results: The annual atrophy rates for each subtype were: SCA: 0.027 ± 0.020 ml/mm, MSA: 0.039 ± 0.026 ml/mm, and CCA: 0.019 ± 0.016 ml/mm. There was a significant difference among subtypes (p = 0.049). The ICARS scores (annual progression) were 4.79 ± 3.86, 8.82 ± 3.93, and 2.31 ± 1.96 for SCA, MSA, and CCA, respectively (p = 0.002).The progression in ICARS per decrease in Vdx of 0.01 ml/mm in MSA, SCA and CCA was measured as 5.9 points,1.8 points and 1.4 points, respectively. Conclusions: The annual atrophy rate and ICARS score (annual progression) were significantly different among subtypes of cerebellar degeneration. MRI-based cerebellar volume measurements can be used as an imaging biomarker for disease progression.

MRI-based Annual Cerebellar Volume Atrophy Rate as a Biomarker of Disease Progression in Patients with Cerebellar Degeneration